Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2018 07:00 ET | Source: uniQure Inc.

uniQure to Host Research & Development Day on Monday, November 19 in New York City

~ Event to be Webcast Live on Corporate Website ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, Nov. 05, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company...
October 31, 2018 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
October 18, 2018 06:55 ET | Source: uniQure Inc.

uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies

~ New Data Presented at the European Society of Gene and Cell Therapy Annual Meeting Demonstrates up to 40 Times Higher Liver Expression with Optimized Promoter ~ LEXINGTON, Mass. and AMSTERDAM, the...
October 17, 2018 07:00 ET | Source: uniQure Inc.

uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

~ Commercial Capacity for AAV Gene Therapy Production Significantly Enhanced by Highly Scalable 500 Liter Reactors ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 17, 2018 (GLOBE NEWSWIRE)...
October 16, 2018 07:00 ET | Source: uniQure Inc.

uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

~ New Data Further Demonstrating Leading Gene Therapy Manufacturing and Administration Capabilities ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 16, 2018 (GLOBE NEWSWIRE) -- uniQure N.V....
September 28, 2018 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 28, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
September 24, 2018 07:00 ET | Source: uniQure Inc.

uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

~ Third patient treated in Phase IIb study ~ ~ Topline data expected to be available before the end of 2018 ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) --...
August 30, 2018 07:00 ET | Source: uniQure Inc.

uniQure to Participate at Multiple Upcoming Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
August 23, 2018 07:00 ET | Source: uniQure Inc.

uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 23, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
August 08, 2018 07:00 ET | Source: uniQure Inc.

uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress

~ Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061 ~ First Patient Successfully Screened into Phase IIb Dose-Confirmation Trial of AMT-061 ~ Robert Gut, M.D., Ph.D.,...